Cargando…

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane

Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Treatment options for ACC are limited, with resection the main intervention. Most cases present in late metastatic cases, and data regarding effective therapies is limited. We report a case of ACC in a 40-year-old woman with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alam, Walid, Bouferraa, Youssef, Haibe, Yolla, Shamseddine, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040600/ https://www.ncbi.nlm.nih.gov/pubmed/33889043 http://dx.doi.org/10.1177/11795549211007682

Ejemplares similares

Management of colorectal cancer in the era of COVID-19: Challenges and suggestions
por: Alam, Walid, et al.
Publicado: (2021)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
por: El Sayed, Rola, et al.
Publicado: (2021)

Thrombotic Microangiopathy in the Setting of Colorectal Cancer: A Therapeutic Challenge with a Bad Prognosis
por: Bouferraa, Youssef, et al.
Publicado: (2023)

From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade
por: Abdel Sater, Ali H., et al.
Publicado: (2022)

The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study
por: Bouferraa, Youssef, et al.
Publicado: (2022)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
por: Oddie, Philip D, et al.
Publicado: (2018)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature
por: Ghorayeb, Nada El, et al.
Publicado: (2016)

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature: Erratum
Publicado: (2016)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
por: Mormando, Marilda, et al.
Publicado: (2023)

Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
por: Bouferraa, Youssef, et al.
Publicado: (2022)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma
por: Weng, Yan, et al.
Publicado: (2023)

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
por: Haak, H. R., et al.
Publicado: (1994)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line
por: Bach, Camila, et al.
Publicado: (2022)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Yongquan, et al.
Publicado: (2018)

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

SUN-216 Investigating the Role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2020)

Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
por: Mota, Jose Mauricio, et al.
Publicado: (2018)

Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
por: Haibe, Yolla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ngtfbnv9ea224ib4acumramv6d